低分子肝素钠抗凝在肝硬化合并门静脉血栓中的应用效果

Abstract
Figure/Table
References (20)
Related Citation (3)

Download: PDF (681 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To explore the effects of low molecular weight heparin anticoagulation in cirrhotic patients with portal vein thrombosis and to assess the impact on patients′ medical costs. Methods From January 2015 to April 2016, 200 cases of cirrhosis patients with portal vein thrombosis in Hengshui Fourth Hospital were selected and divided into the observation group and the control group according to the random number table, with 100 cases in each group. The control group was given routine treatment and the observation group was given low molecular weight heparin sodium anticoagulant 0.4 mL, 1 time a day for six months. The coagulation status, portal vein thrombosis, adverse reactions, hospitalization time and the hospital costs were compared between the two groups. Results After 2 weeks, 1, 2, 4 month and 6 month, the average volume of portal vein thrombosis in the observation group were all lower than those of control group, with statistically significant differences (P ＜ 0.05)； there were no significant differences in prothrombin time and platelet count between the two groups （P ＞ 0.05）. The recanalization rate of portal vein in the observation group was higher than that of control group, with statistically significant difference (P ＜ 0.05). The incidence of complications, hospitalization time and hospitalization cost in the observation group were all lower than that of control group, with statistically significant differences (P ＜ 0.05). Conclusion The application of low molecular weight heparin sodium anticoagulation in the treatment of cirrhosis with portal vein thrombosis can significantly reduce the volume of portal vein thrombosis, improve the recanalization rate, reduce the long-term complications, shorten the hospitalization time and reduce the medical costs.

Key words： Cirrhosis Portal vein thrombosis Low molecular weight heparin Anticoagulant effect

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	LI Qing WANG Lilin

Cite this article:

LI Qing WANG Lilin. Effects of low molecular weight heparin anticoagulation in cirrhotic patients with portal vein thrombosis[J]. 中国医药导报, 2018, 15(4): 69-72.

URL:

http://www.yiyaodaobao.com.cn/EN/ OR http://www.yiyaodaobao.com.cn/EN/Y2018/V15/I4/69

[1] 王学祥.肝硬化合并门静脉血栓的诊治探讨[J].中国现代药物应用，2016，10（11）：106-107
[2] Tekkesin N，Tekkesin M，Kaso G. Thromboelastography for the monitoring of the antithrombotic effect of low-molecular-weight heparin after major orthopedic surgery [J]. A natol J Cardiol，2015，15（11）：932-937.
[3] 刘金芝，胡乃中，许建明.肝硬化合并门静脉血栓形成危险因素及预后研究[J].安徽医科大学学报，2016，51（2）：280-283.
[4] D'Amico M，Pasta F，Pasta L. Thrombophilic genetic factors PAI-1 4G-4G and MTHFR 677TT as risk factors of alcohol，cryptogenic liver cirrhosis and portalvein thrombosis，in a Caucasian population [J]. Gene，2015，568（1）：85-88.
[5] 牛亚慧，韩子岩.肝硬化合并门静脉血栓形成的抗凝治疗研究进展[J].中华临床医师杂志：电子版，2017，11（5）：811-815.
[6] 葛均波，徐永健.内科学[M].8版，北京：人民卫生出版社，2013.
[7] McLaughlin K，Drewlo S，Parker JD，et al. Current Theories on the Prevention of Severe Preeclampsia With Low-MolecularWeight Heparin [J]. Hypertension，2015，66（6）：1098-1103.
[8] 张国顺，刘斌，尚华，等.肝硬化合并门静脉血栓形成的危险因素[J].中国老年学杂志，2016，36（19）：4820-4821.
[9] Kim JY，Jeon OC，Moon HT，et al. Preclinical safety evaluation of low molecular weight heparin-deoxycholate conjugates as an oral anticoagulant [J]. J Appl Toxicol，2016， 36（1）：76-93.
[10] 王万琴，文茂瑶，凡小丽，等.肝硬化合并门静脉血栓的研究进展[J].临床肝胆病杂志，2016，32（7）：1409-1412.
[11] 杨娟，马佳，马莉娜.低分子肝素钙预防断流术后门静脉血栓的临床观察[J].陕西医学杂志，2017，46（8）：1121-1123.
[12] Lisman T. Low molecularweight heparin in management and prevention of portal vein thrombosis [J]. Thromb Res，2014，134（4）：761-762.
[13] 张震.低分子肝素的结构确证研究[J].中国新药杂志，2014，23（8）：901-906.
[14] Kurtcehajic A，Zerem E，Hujdurovic A，et al. Thrombotic risk factors in nonmalignant and noncirrhotic patients with portalvein thrombosis：need for extensive investigation [J]. Eur J Gastroen Hepat，2016，28（1）：116-118.
[15] 徐雷，王芳，张囡囡.不同血栓前状态分子标志物水平对肝硬化合并门静脉血栓形成的预测价值分析[J].中国中西医结合消化杂志，2017，25（5）：384-388.
[16] 薛帅，张强，刘嘉，等.断流术后门静脉血栓的诊疗现状[J].世界华人消化杂志，2016，24（29）：4063-4069.
[17] Nadarajah L，Fan S，Forbes S，et al. Major bleeding in hemodialysis patients using unfractionated or low molecularweight heparin：a single-center study [J]. Clin nephrol，2015，84（11）：274-279.
[18] 陆申新，陈世耀.抗凝治疗肝硬化患者并发症门静脉血栓的循证医学证据[J].实用肝脏病杂志，2016，19（5）：624-628.
[19] Afshari D，Moradian N，Nasiri F，et al. The efficacy and safety of low-molecular-weight heparin and unfractionated heparin in the treatment of cerebral venous sinus thrombosis [J]. Neurosciences，2015，20（4）：357-361.
[20] 赵旭，李婉玉.肝硬化合并门静脉血栓的患者应用抗凝药物达那肝素钠的安全性及有效性研究[J].临床肝胆病杂志，2015，31（5）：732-732.